benefit milligrams measure cognitive function search perfect dose definitive proof drug potency continue upcoming year study meantime researchers eli lilly described potentially encouraging results extension large failed trial solanezumab highlight monoclonal antibody efficacy focused patients early disease called delayed start analysis alzheimer drug start 3.5 year trial randomly assigned 1,322 patients placebo active treatment 80 weeks placebo group began taking solanezumab groups continued worsening symptoms treatment slow pace significance placebo group never caught cognitive scores patients received solanezumab start researchers interpret finding tantalizing evidence drug mopping beta amyloid brain tempering toxicity simply treating symptoms delayed start control group gains group